NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 13 pharmaceutical companies such as ALEMBIC PHARMS LTD, SANDOZ, APOTEX INC and others. It is marketed under 3 brand names, including RIVASTIGMINE TARTRATE, EXELON, RIVASTIGMINE. Available in 7 different strengths, such as EQ 1.5MG BASE, EQ 3MG BASE, EQ 4.5MG BASE and others, and administered through 2 routes including CAPSULE;ORAL, FILM, EXTENDED RELEASE;TRANSDERMAL.
API availability: Loading API feasibility...
Licensing: 13 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
No US Orange Book patents found
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Rivastigmine
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.